Companion Diagnostic Test

IN VITRO DIAGNOSTICS

In vitro diagnostics (IVD) are tests conducted on human samples, which may be used in precision medicine to determine and guide the applicability of targeted therapy, immunotherapy or other drug treatment for cancer patients.

Our extensive NGS-based IVD tests development and first-in-class kit manufacturing facilities make us an excellent partner in accelerating the commercialization of your therapeutic product.

CE-IVD ApprovedNMPA Approved

CE-IVD Approved

GENESEEQPRIME™

GENESEEQ PRIME NGS Tumor Gene Detection Kit

437-gene panel, TMB, MSIFor all solid tumors

Learn more about GeneseeqPrime™

GENESEEQPRIME™ HRD

GENESEEQ HRD (Homologous Recombination Deficiency) Detection Kit

Genome-wide HRD score437-gene panel, TMB, MSIFor all solid tumors

Learn more about GeneseeqPrime™ HRD

HEMASALUS™

GENESEEQ Blood Cancer Gene Detection Kit

475 gene at DNA level232 fusion genes at RNA levelFor all hematologic malignancies

Learn more about HEMASALUS™

SHIELDING™ ULTRA

Geneseeq Multi-Cancer Minimal Residual Disease Detection Kit

A full-course perioperative MRD monitoring 2365 cancer-related genes for solid tumors

Learn more about Shielding™ Ultra

CANSCAN™

Geneseeq Multi-Cancer Early Detection Kit

Multi-cancer early detection (MCED)Assess multi-omics features of cfDNA through blood test

NMPA Approved

ESSENCARE™ CDx

EGFR/ALK/ROS1/BRAF/KRAS/HER2 mutation testing kit

Reversible terminator sequencing

  • NGS-based test approved by Chinese National Medical Products Administration (NMPA)
  • Ultra-high analytical sensitivities:
    • 1% for substitutions (SNPs) and insertion/deletions (indels)
    • 2.5% for gene rearrangements (fusions)
WHO IS IT FOR

Non-small cell lung cancer (NSCLC) patients seeking targeted therapy

SAMPLE TYPES
Icon Tumour Tissue

FFPE Tumor tissue

Essencare™ Report

  • Companion diagnostic test for targeted therapy

BIOMARKER
NMPA-APPROVED THERAPY*
EGFR exon 19 deletion & EGFR L858R
Iressa® (gefitinib), Conmana® (Icotinib)
EGFR T790M
Tagrisso® (osimertinib)
ALK rearrangements
Xalkori® (crizotinib)
ROS1 rearrangements
Xalkori® (crizotinib)

*Iressa® and Tagrisso® are registered trademarks of the AstraZeneca group of companies. Xalkori® is a registered trademark of Pfizer Inc. Conmana® is a registered trademark of Betta Pharmaceuticals.

  • Other biomarkers tested

GENE NAME
MUTATIONS
EGFR
G719 mutations, L861Q
BRAF
V600E
KRAS
G12 and G13 mutations
HER2
exon20 insertions
Contact us today to learn more about Essencare™

GENESEEQPRIME™ TMB

Non-Small Cell Lung Cancer Tumor Mutational Burden Test Kit

Reversible terminator sequencing

  • NGS-based test approved by Chinese National Medical Products Administration (NMPA)
  • An overall concordance rate of over 90% compared to the gold standard WES-TMB
  • Limit of detection has been demonstrated to be at 2% VAF for various common variant types or 5% tumor cell content in the reference samples
WHO IS IT FOR

Non-small cell lung cancer (NSCLC) patients seeking immune checkpoint inhibitor therapy

SAMPLE TYPES
Icon Tumour Tissue

FFPE Tumor tissue

LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.

Learn more about our products and services or contact us today to discuss how we can partner together.

Contact Us